Is NeuroMetrix Stock a Good Investment?
NeuroMetrix Investment Advice | NURO |
- Examine NeuroMetrix's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research NeuroMetrix's leadership team and their track record. Good management can help NeuroMetrix navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact NeuroMetrix's business and its evolving consumer preferences.
- Compare NeuroMetrix's performance and market position to its competitors. Analyze how NeuroMetrix is positioned in terms of product offerings, innovation, and market share.
- Check if NeuroMetrix pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about NeuroMetrix's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in NeuroMetrix stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if NeuroMetrix is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine NeuroMetrix Stock
Researching NeuroMetrix's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 25.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.54. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeuroMetrix recorded a loss per share of 4.51. The entity last dividend was issued on the 28th of March 2007. The firm had 1:8 split on the 22nd of November 2023.
To determine if NeuroMetrix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NeuroMetrix's research are outlined below:
| NeuroMetrix had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (6.53 M) with profit before overhead, payroll, taxes, and interest of 5.75 M. | |
| NeuroMetrix currently holds about 20.83 M in cash with (6.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68. | |
| NeuroMetrix has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Disposition of 498 shares by Thomas Higgins of NeuroMetrix at 3.03 subject to Rule 16b-3 |
NeuroMetrix Quarterly Cash And Short Term Investments |
|
NeuroMetrix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NeuroMetrix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NeuroMetrix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact NeuroMetrix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises NeuroMetrix's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-01-24 | 2018-12-31 | -1.4 | -2.01 | -0.61 | 43 | ||
2018-04-19 | 2018-03-31 | -0.58 | 0.08 | 0.66 | 113 | ||
2018-07-19 | 2018-06-30 | -0.35 | 0.4 | 0.75 | 214 | ||
2021-10-21 | 2021-09-30 | -1.8 | -0.96 | 0.84 | 46 | ||
2020-01-27 | 2019-12-31 | -1.8 | -3.0 | -1.2 | 66 | ||
2021-04-22 | 2021-03-31 | -1.8 | -0.16 | 1.64 | 91 | ||
2018-10-17 | 2018-09-30 | -0.19 | 1.5 | 1.69 | 889 | ||
2021-07-22 | 2021-06-30 | -1.8 | -0.09 | 1.71 | 95 |
Know NeuroMetrix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NeuroMetrix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeuroMetrix backward and forwards among themselves. NeuroMetrix's institutional investor refers to the entity that pools money to purchase NeuroMetrix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Corecap Advisors, Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 15.1 K | Geode Capital Management, Llc | 2024-09-30 | 13.8 K | Advisor Group Holdings, Inc. | 2024-06-30 | 6.7 K | Blackrock Inc | 2024-06-30 | 5 K | Tower Research Capital Llc | 2024-06-30 | 1.7 K | Tucker Asset Management Llc | 2024-06-30 | 402 | Accent Capital Management Llc | 2024-09-30 | 300 |
NeuroMetrix's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.62 M.Market Cap |
|
NeuroMetrix's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.32) | (0.34) |
Determining NeuroMetrix's profitability involves analyzing its financial statements and using various financial metrics to determine if NeuroMetrix is a good buy. For example, gross profit margin measures NeuroMetrix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NeuroMetrix's profitability and make more informed investment decisions.
Evaluate NeuroMetrix's management efficiency
NeuroMetrix has return on total asset (ROA) of (0.2821) % which means that it has lost $0.2821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4278) %, meaning that it created substantial loss on money invested by shareholders. NeuroMetrix's management efficiency ratios could be used to measure how well NeuroMetrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, NeuroMetrix's Non Currrent Assets Other are very stable compared to the past year. As of the 27th of November 2024, Other Current Assets is likely to grow to about 1.5 M, while Total Assets are likely to drop about 17.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 19.28 | 18.32 | |
| Tangible Book Value Per Share | 19.28 | 18.32 | |
| Enterprise Value Over EBITDA | (0.32) | (0.30) | |
| Price Book Value Ratio | 0.19 | 0.18 | |
| Enterprise Value Multiple | (0.32) | (0.30) | |
| Price Fair Value | 0.19 | 0.18 | |
| Enterprise Value | 2.3 M | 2.1 M |
The strategic initiatives led by NeuroMetrix's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 2.301 |
Basic technical analysis of NeuroMetrix Stock
As of the 27th of November, NeuroMetrix secures the Mean Deviation of 2.64, risk adjusted performance of 0.081, and Downside Deviation of 3.16. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeuroMetrix, as well as the relationship between them.NeuroMetrix's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeuroMetrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeuroMetrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeuroMetrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeuroMetrix's Outstanding Corporate Bonds
NeuroMetrix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NeuroMetrix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NeuroMetrix bonds can be classified according to their maturity, which is the date when NeuroMetrix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US64128XAE04 Corp BondUS64128XAE04 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand NeuroMetrix's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing NeuroMetrix's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.081 | |||
| Market Risk Adjusted Performance | (1.79) | |||
| Mean Deviation | 2.64 | |||
| Semi Deviation | 2.91 | |||
| Downside Deviation | 3.16 | |||
| Coefficient Of Variation | 1043.97 | |||
| Standard Deviation | 3.43 | |||
| Variance | 11.75 | |||
| Information Ratio | 0.0583 | |||
| Jensen Alpha | 0.3394 | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | 0.0632 | |||
| Treynor Ratio | (1.80) | |||
| Maximum Drawdown | 15.39 | |||
| Value At Risk | (4.75) | |||
| Potential Upside | 6.09 | |||
| Downside Variance | 10.0 | |||
| Semi Variance | 8.49 | |||
| Expected Short fall | (3.05) | |||
| Skewness | 0.2255 | |||
| Kurtosis | 0.1986 |
| Risk Adjusted Performance | 0.081 | |||
| Market Risk Adjusted Performance | (1.79) | |||
| Mean Deviation | 2.64 | |||
| Semi Deviation | 2.91 | |||
| Downside Deviation | 3.16 | |||
| Coefficient Of Variation | 1043.97 | |||
| Standard Deviation | 3.43 | |||
| Variance | 11.75 | |||
| Information Ratio | 0.0583 | |||
| Jensen Alpha | 0.3394 | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | 0.0632 | |||
| Treynor Ratio | (1.80) | |||
| Maximum Drawdown | 15.39 | |||
| Value At Risk | (4.75) | |||
| Potential Upside | 6.09 | |||
| Downside Variance | 10.0 | |||
| Semi Variance | 8.49 | |||
| Expected Short fall | (3.05) | |||
| Skewness | 0.2255 | |||
| Kurtosis | 0.1986 |
Consider NeuroMetrix's intraday indicators
NeuroMetrix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NeuroMetrix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 430.3 | |||
| Daily Balance Of Power | 0.15 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 4.29 | |||
| Day Typical Price | 4.28 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | 0.03 |
NeuroMetrix Corporate Filings
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 27th of September 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 31st of May 2024 Other Reports | ViewVerify |
NeuroMetrix Stock media impact
Far too much social signal, news, headlines, and media speculation about NeuroMetrix that are available to investors today. That information is available publicly through NeuroMetrix media outlets and privately through word of mouth or via NeuroMetrix internal channels. However, regardless of the origin, that massive amount of NeuroMetrix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NeuroMetrix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeuroMetrix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeuroMetrix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeuroMetrix alpha.
NeuroMetrix Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards NeuroMetrix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NeuroMetrix Corporate Executives
Elected by the shareholders, the NeuroMetrix's board of directors comprises two types of representatives: NeuroMetrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuroMetrix. The board's role is to monitor NeuroMetrix's management team and ensure that shareholders' interests are well served. NeuroMetrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuroMetrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Higgins | CFO, Principal Accounting Officer, Sr. VP and Treasurer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.51) | Revenue Per Share 2.157 | Quarterly Revenue Growth (0.51) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between NeuroMetrix's value and its price, as these two are different measures arrived at by various means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.